However, p53 mutation and inactivation and MDM2/MDMX overexpression and amplification are frequently observed in various types of human cancer, and the current MDM2/MDMX inhibitors have low or no efficacy in patients with these cancers (Bohlman and Manfredi, 2014; Wang et al., 2014a, b). This evidence concerns the gene MDM4 and cancer.